Waching daily Apr 3 2018

Diabetes medication plunges blood sugar to dangerously low levels, increasing risk of

heart attack and death Saturday, March 31, 2018 by: Ethan Huff

The American College of Physicians (ACP) has released an updated guidance statement about

how to treat type-2 diabetes that significantly scales back the group's official recommendations

concerning drug-based interventions for the blood sugar condition.

Because pharmacologic therapies for type-2 diabetes come with some serious health risks,

the ACP is now recommending that physicians take a more conservative approach in administering

them.

Rather than try to achieve what are now being regarded as impossibly low blood sugar level

targets, the ACP says that doctors should instead focus on more minor reductions.

The problem is that too many type-2 diabetics are suffering heart attacks and early death

as a result of taking the pharmaceuticals prescribed by their doctors.

Based on the latest available data about some of the newer type-2 diabetes drugs on the

market today, the ACP is advising that physicians instead pay more attention to potential adverse

effects, and focus less on simply trying to bring down blood sugar levels.

"Some anticipate that treatment decisions will eventually be based more on cardiovascular

risk than achievement of specific HbA1c (hemoglobin A1c) targets, analogous to recent changes

in lipid management," the guidance explains.

Guidance admits that drug treatment harms outweigh benefits in many patients

To come to this conclusion, experts at the ACP pored through the National Guideline Clearinghouse

and the Guidelines International Network library, looking specifically at recommended HbA1c

targets and how they work in treating non-pregnant type-2 diabetics.

They considered recommendations from various national organizations, as well as titles

and abstracts in the scientific literature that were relevant to the subject at hand.

A total of six co-authors independently reviewed and assessed each gathered guideline using

the Appraisal of Guidelines for Research and Evaluation II, also known as AGREE II, to

evaluate each piece of the treatment puzzle.

They then provided their own summary determinations of whether or not they would recommend the

varying guidelines.

In the end, they found that many of the most commonly employed treatment regimens for type-2

diabetes are too aggressive, putting patients at risk of serious complications – most

notably heart disease.

While blood sugar levels were found to be reduced using such methods, in many cases

these treatments result in a litany of health damage.

Based on this comprehensive assessment, it was determined that, in many cases, the harms

far outweigh the benefits when it comes to using pharmaceutical drugs in the vigorous

treatment of type-2 diabetes – so much so that the experts now recommend that doctors

aim for an HbA1c target of between 7 and 8 percent, depending on a patient's particular

treatment regimen.

Patients with co-morbid conditions or limited life expectancy can have even higher targets,

the guidance explains, as they have an even higher risk of complications arising from

drug treatments.

All the way around, HbA1c targets were determined to be more appropriate at higher amounts than

the current norm, illustrating that today's type-2 diabetes treatments are just too risky

for comfort in many cases.

"Clinicians should personalize goals for glycemic control in patients with type 2 diabetes

on the basis of a discussion of benefits and harms of pharmacotherapy, patients' preferences,

patients' general health and life expectancy, treatment burden, and costs of care," the

guidance concludes.

"Clinicians should aim to achieve an HbA1c level between 7 percent and 8 percent in most

patients with type 2 diabetes."

Further, the guidance suggests "deintensifying" pharmacologic therapy in patients with type-2

diabetes who achieve HbA1c levels below 6.5 percent.

"Clinicians should treat patients with type 2 diabetes to minimize symptoms related to

hyperglycemia and avoid targeting an HbA1c level in patients with a life expectancy less

than 10 years due to advanced age (80 years or older), residence in a nursing home, or

chronic conditions (such as dementia, cancer, end-stage kidney disease, or severe chronic

obstructive pulmonary disease or congestive heart failure) because the harms outweigh

the benefits in this population."